Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590 · clinicaltrials.gov ↗

COMPLETED

Status

1710

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab

Sponsor

Hoffmann-La Roche